• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Russians Threaten to Sue Over Vaccine Switch-Up — Reports

firstwordpharmaJune 22, 2021

Tag: COVID-19 , Vaccine , Sputnik V

Several Russian volunteers who claim they were given a less effective COVID-19 vaccine instead of the Sputnik V vaccine are considering pursuing legal action, as reported The Moscow Times on Monday.

Russians Threaten to Sue Over Vaccine Switch-Up — Reports

Seven patients said they were either misled into thinking they had received Sputnik V or met with a lack of Sputnik V doses at their vaccination sites, and were inoculated with EpiVacCorona.

Vektor Institute, which developed EpiVacCorona last year, said recently that nearly half of EpiVacCorona recipients lacked antibodies nine months after receiving the vaccine.

Russian health officials previously said that EpiVacCorona had 100% efficacy, according to the news source.

Previous:US approval for OTC use of Bayer’s Astepro

Next:Novartis’ radioligand therapy granted US Breakthrough Therapy Designation

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Russians Threaten to Sue Over Vaccine Switch-Up — Reports | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological

Hualan bio Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological
Influenza Vaccine by Hualan Bio

Influenza Vaccine by Hualan Bio
WHO-PQ Influenza Vaccine

WHO-PQ Influenza Vaccine
Poultry Vaccine Series

Poultry Vaccine Series
Human Vaccine

Human Vaccine
Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)

Enterovirus Type 71 Vaccine, Inactivated (Human Diploid Cell)
Hualan BIO Influenza Vaccine (Split virion)

Hualan BIO Influenza Vaccine (Split virion)
Hualan inactivated flu vaccine

Hualan inactivated flu vaccine
Qualified Trivalent Influenza Vaccine

Qualified Trivalent Influenza Vaccine
Good immunogenicity performance Influenza Vaccine (Split virion)

Good immunogenicity performance Influenza Vaccine (Split virion)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service